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Bacterial adhesion to biomaterials remains a major problem in the medical devices ﬁeld. Antimicrobial
peptides (AMPs) are well-known components of the innate immune system that can be applied to over-
come bioﬁlm-associated infections. Their relevance has been increasing as a practical alternative to con-
ventional antibiotics, which are declining in effectiveness. The recent interest focused on these peptides
can be explained by a group of special features, including a wide spectrum of activity, high efﬁcacy at very
low concentrations, target speciﬁcity, anti-endotoxin activity, synergistic action with classical antibiotics,
and low propensity for developing resistance. Therefore, the development of an antimicrobial coating
with such properties would be worthwhile. The immobilization of AMPs onto a biomaterial surface
has further advantages as it also helps to circumvent AMPs’ potential limitations, such as short half-life
and cytotoxicity associated with higher concentrations of soluble peptides. The studies discussed in the
current review report on the impact of covalent immobilization of AMPs onto surfaces through different
chemical coupling strategies, length of spacers, and peptide orientation and concentration. The overall
results suggest that immobilized AMPs may be effective in the prevention of bioﬁlm formation by reduc-
tion of microorganism survival post-contact with the coated biomaterial. Minimal cytotoxicity and long-
term stability proﬁles were obtained by optimizing immobilization parameters, indicating a promising
potential for the use of immobilized AMPs in clinical applications. On the other hand, the effects of teth-
ering on mechanisms of action of AMPs have not yet been fully elucidated. Therefore, further studies are
recommended to explore the real potential of immobilized AMPs in health applications as antimicrobial
coatings of medical devices.
 2010 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.Introduction
The use of biomaterial implants and medical devices such as
catheters, heart valves, stents, shunts, arthoprostheses and fracture
ﬁxation devices is an increasingly common and often life-saving
procedure. Although infection incidence has been reduced by asep-
tic surgical techniques and prophylactic systemic antibiotic ther-
apy, bacterial colonization of medical devices or implants still
represents a serious hazard [1–3]. Mortality attributable to such
infections is highest among patients with cardiovascular implants,
particularly prosthetic heart valves and aortic grafts. However,
infections associated with orthopaedic devices often result in seri-
ous disabilities [4]. These infections may cause implant failure,
complex revision processes and implant removal, all leading to
patient suffering, prolonged hospitalization and even death [5].
Implant-associated infections are classiﬁed in three ways:
superﬁcial immediate infections, deep immediate infections andia Inc. Published by Elsevier Ltd. A
. Martins).deep late infections. Superﬁcial immediate infections are caused
by bacteria that normally populate the skin and start to colonize
the medical device (e.g. infected sutures). Deep immediate infec-
tions become apparent shortly after invasive surgeries and may
be due to inadvertent relocation of skin bacteria into the body,
i.e. non-sterile implantation procedures. Finally, deep late infec-
tions appear months or years after surgery and may be a delayed
display of contamination that was seeded during surgery or
resulted from bacteria that migrated from another anatomic site [6].
Implant surface susceptibility to infection is dependent on the
immune system performance and on the activity and virulence of
the involved microorganisms [2,7]. Immune system performance
can be compromised by direct surgical trauma, implant presence,
low availability of blood vessels in the implant vicinity and inﬂam-
matory escalation, frequently resulting in peri-implant tissue dam-
age. The activity and virulence of microorganisms are correlated
with their capacity for bioﬁlm formation [8]. Bioﬁlms can colonize
almost every kind of material (metals, ceramics and polymers) and
therefore medical devices [9]. Bioﬁlms are a differentiated, high-
density population of microorganisms that are surrounded by all rights reserved.
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of polysaccharides, proteins, nucleic acids and lipids produced
simultaneously by the microorganisms in the bioﬁlm [3] and by
proximal host cells [10,11]. This bioﬁlm matrix is characterized
by its resistance to stressful environmental conditions such as
UV radiation, pH variation, osmotic shock, desiccation and ﬂow
conditions, and additionally by prevention of the entrance of
antibiotics and biocidal substances [9]. Furthermore, the bioﬁlm
structure facilitates horizontal gene transfer between resistant
and non-resistant microbial strains [9]. The overall result is an
antibiotic resistance that is typically 10–1000 higher in bioﬁlms
than in the planktonic form of the same bacterial species
[9,12,13]. Moreover recent research data have demonstrated that
sub-therapeutic doses of both classical and recent antibiotics
may induce speciﬁc gene expression, resulting in the paradoxical
effect of exarcebating bioﬁlm formation [14–17].
Bioﬁlm establishment results from a speciﬁc sequence of events:
microbial adherence, microcolony formation and proliferation, ma-
trix production, bioﬁlm maturation and, ﬁnally, cell detachment
with propagation of infection [2,3]. Therefore, bioﬁlms may repre-
sent reservoirs for the development of pathogenic infections [2,3].
When a biomaterial is implanted, a conditioning layer primarily
composed of proteins (ﬁbronectin, vitronectin, ﬁbrinogen, albumin
and immunoglobulins) adheres to its surface, favouring surface–
microorganism interactions [5,13]. The interaction between bacte-
ria and surface proteins results initially fromweak attraction forces
such as Van der Waals and electrostatic charges, which are later
reinforced by speciﬁc interactions involving bacterial adhesion pro-
teins [9]. Further, cell adhesion is facilitated by bacterial signalling
and matrix production, yielding a mature bioﬁlm [2,13]. After for-
mation, a bioﬁlm cannot be easily eliminated by standard clinical
procedures, and the infection often can only be eradicated by the
removal of the infected implant. In order to solve this problem, re-
search has been conducted on the development of antimicrobial
surface coatings that can prevent the initial bacterial colonization
and/or actively reduce bacterial titres, minimizing the potential
for bioﬁlm formation [2,10].2. Antimicrobial coatings
In order to avoid implant-associated infections, several strate-
gies have been reported with the aim of creating antimicrobial sur-
faces, such as the development of (i) non-fouling surfaces (surfaces
that avoid protein adsorption and cell adhesion) [1,18–20], (ii) sur-
faces previously colonized with non-pathogenic bacteria [9], (iii)
surfaces combined with biocidal substances [21–23] and (iv) sur-
faces combined with antibiotics [24–26].
The physicochemical properties of the implant surface, such as
surface roughness energy and potential, are fundamental issues in
the initial adhesion and subsequent growth of bacteria. Non-fouling
surfaces combine one or more approaches in order to inﬂuence the
amount and/or conformation of adsorbed proteins, preventing bac-
terial adhesion and bioﬁlm formation. Some examples are UV radi-
ation of titanium surfaces to augment wettability [27], use of
anti-adherent agents bearing negative charges [28], polymer
coatings such as poly(ethylene glycol) (PEG), poly(hydroxyethyl-
methacrylate) (PHEMA) [18,29], poly(methacrylic acid) [30], poly-
urethanes [31] or even bioactive polymers such as chitosan,
which possess the ability to inhibit bacterial adhesion and/or to kill
adherent bacteria [32]. Unfortunately, the effectiveness of
non-fouling coatings for reducing bacterial adhesion is limited
and varies greatly depending on bacterial species.
Another approach involves the simultaneous use of an antimi-
crobial agent and a non-pathogenic bacterial coating layer. The
non-pathogenic bacteria, resistant to a speciﬁc antimicrobial isused to populate the ecological space, preventing adherence of
pathogenic bacteria to the surface [9].
Surfaces combined with antibiotics or other biocidal substances
have the advantage of delivering drugs directly to the implant site,
resulting in locally high drug doses without exceeding the systemic
toxicity level of the drug, thus preventing harmful side effects [3].
Several antimicrobial surfaces have been described in the litera-
ture, including non-antibiotic antimicrobial agents such as silver,
salicylic acid, quaternary ammonium compounds, phenol deriva-
tives, chlorhexidine and nitric oxide [3,5,13,33]. However, many
of these compounds are associated with anaphylaxis, cytotoxicity
or low efﬁciency [5,13]. These limiting aspects prompt the use of
true antibiotics such as vancomycin, tobramycin, cefalozin,
teicoplanin, carbenicillin, amoxicillin, penicillin, ampicillin and
gentamicin [3,34–37], through two different strategies: sub-
stance-releasing coating and substance covalent immobilization.
The release strategy offers the potential for extended activity, but
has to date failed to achieve delivery of a sustained and effective
dosage over a relatively prolonged period of time. To address this
issue, there has been an increased interest in covalent attachment
of drugs to the implant surface to achieve long-lasting antibacterial
activity. For example, vancomycin has been successfully attached
to titanium and proven to be bactericidal to Staphylococcus aureus
and Staphylococcus epidermidis [5,7]. In addition, Aumsuwan et al.
[34,37] reported the covalent attachment of penicillin and ampicil-
lin to expanded polytetraﬂuoroethylene (ePTFE). When these drugs
were immobilized through a PEG-spacer, the surfaces displayed
high antimicrobial efﬁciency among their spectrum of activity,
indicating that antibiotic mobility is essential to activity. The
advantages of covalent attachment to the implant surface are
long-lasting antimicrobial activity, low incidence of side effects
and non-accumulation in tissues (brain, liver and spleen) [5]. How-
ever, the effectiveness of coatings with classical antibiotics is
strongly dependent on the spectrum of activity of the chosen drug,
and the possibility of development of antimicrobial resistance in a
relatively short time period [38]. Therefore, alternative answers
must be developed. There is a clear need for a broad-spectrum
antimicrobial that prevents colonization of biomaterials, mini-
mizes the development of bacterial resistance, displays long-term
stability, even through the sterilization process, and has a low
cytotoxic proﬁle. Antimicrobial peptides have the potential to meet
these criteria [39–42] and therefore represent a promise for the
new generation of antimicrobial surfaces.3. Antimicrobial peptides
In the past 50 years, resistance to new antibiotics has appeared
in microbial populations within a few years of the introduction of a
new therapeutic drug [38]. The decline in the effectiveness of cur-
rent therapies has led to a search for new kinds of agents, including
antibiotics based on antimicrobial peptides (AMPs), which are part
of the innate immune system of all multicellular organisms
[39–43]. So far, more than 750 different AMPs have been isolated
from a wide variety of animals, plants, bacteria, fungi and viruses
[39–42,44]. The AMPs comprise a chemically and structurally het-
erogeneous family. Nevertheless, three characteristics that are
shared by almost all known AMPs can be distinguished: (i) small
size (10–25 amino acids), with molecular weights (MW) between
1 and 5 kDa; (ii) highly cationic character, though with large vari-
ations in the net positive charge; (iii) tendency to adopt amphi-
pathic structures, i.e. structures with separate hydrophobic and
hydrophilic domains, in non-polar media. Because of these physi-
cochemical characteristics, AMPs have the tendency to associate
with negatively charged microbial surfaces and membranes [45].
These peptides offer several attractive advantages: they exhibit
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act at a very low concentration, and they are less likely to promote
bacterial resistance. These properties make AMPs promising candi-
dates for therapeutic drugs [44]. Unlike conventional antibiotics
such as penicillin, which microbes readily deceive, acquisition of
resistance by a sensitive microbial strain against AMPs is less prob-
able. Because the target of AMPs is the bacterial membrane, a
microorganism would have to redesign its membrane, changing
the composition and/or organization of its lipids, which represent
an expensive solution for most microbial species.
However, some resistance mechanisms have been reported in
Gram-positive and Gram-negative bacteria. For instance, some
Gram-positive bacteria (e.g. S. epidermidis, S. aureus) can express
an AMP sensor system that has been proposed to regulate selected
resistance genes when the bacteria come into contact with AMPs
[46–48]. These resistance genes include dlt-operon, which is
responsible for D-alanylation of teichoic acid; mprF, which medi-
ates the incorporation of lysyl-phosphatidylglycerol in the cyto-
plasmic membrane (both of these genes decrease the negative
net charge of the cell envelope); and the vraFG genes of a transport
system [46,47,49–51]. Other reported resistance mechanisms in-
clude protease inhibitors, such S. aureus IsdA surface protein [52],
and bioﬁlm stabilizers such exopolysaccharide intercellular adhe-
sin (PIA) [53]. Nevertheless, bacterial resistance mechanisms to
AMPs differ with regard to efﬁciency, speciﬁcity and distribution
among species [46], and natural AMPs have evolved to avoid some
of these resistance mechanisms. Moreover, synthetic AMPs can be
rationally engineered to circumvent speciﬁc bacterial resistance
mechanisms based on the speciﬁc application (target bacteria,
environment, etc.).
Most peptides are created from nondescript sequences of amino
acids lacking unique motifs that could serve as the recognition site
of a protease required for selective destruction of the antibiotic in
the presence of cellular protein constituents [54]. Furthermore,
some cationic peptides bind to lipopolysaccharide (LPS) and
lipoteichoic acid (LTA) with high afﬁnity (competitively displacing
membrane-stabilizing bivalent cations Ca2+ or Mg2+), disrupting
these sites and leading to enhanced uptake of cationic peptides
across the outer membrane. Disruption of outer membranes can
also lead to promotion of uptake of conventional antibiotics across
the outer membrane, leading to an ‘‘enhancement’’ effect. This self-
promoted uptake process is responsible for two additional advan-
tages: anti-endotoxin activity, in contrast to other antibiotics,
which induce endotoxinaemia, and ‘‘enhancer’’ activity (i.e. syn-
ergy with classical antibiotics) [45,55,56]. The more resistant an
isolate is to a given antibiotic, the more profound is the ‘‘enhance-
ment’’ effect by an appropriate cationic peptide. Thus cationic pep-
tides also have the ability to serve as anti-resistance compounds
[45,55].
The properties of natural AMPs have prompted research towards
de novo AMPs, i.e. fully synthetic peptides. These are distinct from
those innature,with simpler but rationally engineered composition,
obtained by varying the amino acid content and sequence and
overall peptide length to achieve enhanced activity and very low
cytotoxic properties [57]. For example, Mietzner and co-workers
[58–61] have developed a series of de novo peptides based on
structure–function properties observed in natural AMPs. They engi-
neered the peptide composition to achieve enhancedpotency, selec-
tivity and stability. They performed extensive in vitro and in vivo
(intravenous murine infection model and intraperitoneal mouse
infection model) studies in order to evaluate the antimicrobial
activity (against Pseudomonas aeruginosa, S. aureus, Streptococcus
gordonii, Fusobacterium nucleatum and Porphyromonas gingivalis),
cytotoxicity (towards red blood cells, white blood cells, human skin
ﬁbroblasts), and salt resistance (towards NaCl, Mg2+ and Ca2+). The
engineered peptide derivative WLBU2 (RRWVRRVRRWVRRVVRVVRRWVRR) was identiﬁed as a promising prophylactic and therapeu-
tic molecule. The in vitro studies revealed good selectivity, and po-
tency at physiological conditions (salt resistance), which was
reinforced by in vivo efﬁcacy in the intravenous and intraperitoneal
P. aeruginosa infection models.
Finally, the potential of future AMP-based drugs is underlined
by the number of clinical trials with various AMP species for treat-
ment of skin and soft tissue infections, oral mucositis and paediat-
ric sepsis [44,62,63].
3.1. Mode of antibacterial action
AMPs target the fundamental difference in the membrane
structures of microorganisms and multicellular animals. Bacterial
membranes are organized in such a way that the outermost leaﬂet
of the bilayer is heavily occupied by lipids with negatively charged
phospholipid headgroups. In contrast, the outer leaﬂet of the mem-
branes of plants and animals is composed principally of lipids with
no net charge. Here most of the lipids with negatively charged
headgroups are segregated into the inner leaﬂet, facing the cyto-
plasm [54].
Although the exact mechanism of action of AMPs remains a
matter of controversy, there is a consensus that the following se-
quence occurs: (i) cationic, i.e. positively charged, peptides are
electrostatically attracted to the negatively charged microbial cell
membranes, and (ii) upon binding to the phospholipid membrane,
the AMP adopts an amphipathic structure, adapting to the speciﬁc
conditions at the membrane–water interface. Most AMPs only as-
sume their amphipathic structure upon interaction with the mem-
brane, as it is not the most favoured structure in water. This
interaction is generally believed to lead to a lethal increase in the
permeability of the cell membrane [45]. How this interaction ends
in fatal outcome still remains to be determined. Many hypotheses
have been presented, which include: fatal depolarization of the
normally energized bacterial membrane; creation of physical holes
resulting in leakage of cellular contents; activation of deadly pro-
cesses such as induction of hydrolases that degrade the cell wall;
alteration of the usual distribution of lipids between the leaﬂets
of the bilayer that results in disturbance of membrane functions;
and damage to the critical intracellular targets after internalization
of the peptide [54]. Recently, it has been shown that peptide reori-
entation together with membrane destabilization happens after a
certain peptide threshold concentration is achieved. This can be
ascribed to a ﬁrst step of membrane surface coverage by the
AMP until charge neutralization is reached. Thereafter, peptide
orientation changes from parallel to perpendicular to the
membrane surface, followed by pore formation and eventually
membrane disruption [64–66].
Based on the available data, three models explaining the mode
of action of AMPs have been proposed (Fig. 1).
(i) The carpet model: After the microbial cell membrane is fully
covered by a carpet-like cluster of peptides, a saturation
point is reached that results in extensive wormhole forma-
tion, causing the abrupt lysis of the microbial cell. Cell lysis
is believed to result as the lipid layer bends back on itself,
with lateral expansions in the polar head-group region, pro-
viding the gaps that will be ﬁlled up by individual peptide
molecules.
(ii) The toroidal pore model: After binding to the phospholipid
head groups, the peptides insert into the membrane and
then cluster into unstructured bundles that span the mem-
brane. These bundles, in association with water molecules,
are believed to create channels responsible for leakage of
ions and possibly larger molecules throughout the mem-
brane. This last model differs from the other two in that only
Fig. 1. Current models of the mechanism of action of membrane-active antimicrobial peptides (AMPs): (A) carpet model; (B) toroidal pore model; (C) barrel-stave model.
Adapted with permission from Ref. [64].
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are formed, which allows the peptides to cross the mem-
brane without causing signiﬁcant membrane depolarization.
Once inside, the peptides home on their intracellular targets
to exert their killing activities [45].
(iii) The barrel-stave model: After initial electrostatic binding to
the outer leaﬂet of the bacterial membrane, a-helical amphi-
pathic peptides group together into barrel-like bundles that
line amphipathic transmembrane pores. The non-polar side
chains associate with the hydrophobic fatty acid tails at
the inside of the phospholipid bilayer, and the hydrophilic
side-chains are oriented inward into the water-ﬁlled pore.
Taking into consideration the proposed theories for soluble
AMPs, one could expect that immobilized AMPs would lose their
antimicrobial activity completely or to a large extent. However,
the research reviewed herein proves differently, and even provides
some insights into the speciﬁc mechanisms underlying this activ-
ity. Haynie et al. [67] was able to demonstrate that immobilized
magainin that is attached through very short linkers (2 or 6 carbon
atoms) displays antimicrobial activity, meaning that outer
membrane interaction by magainin is sufﬁcient for lethal activity.
Humblot et al. [68] reported that the immobilized AMPs had a bac-
teriostatic rather that bactericidal effect, perhaps due to the low
peptide concentration or short contact time. Other research has
performed the immobilization through long linkers in an attempt
to permit sufﬁcient ﬂexibility to penetrate target cell membranes
[1,69,70], as the directly attached AMPs lost their antimicrobial
activity. Hilpert et al. [71], in their screening and characterization
of surface-tethered cationic peptides studies, reported that the
immobilization of peptides to a surface should result in constraints
on the peptide mobility and on the capacity of peptides to enter or
even transpose the cellular membranes. Scanning electron micros-
copy (SEM), ATP release and depolarization assays performed with
short peptides indicated that, although their length was insufﬁ-
cient to stretch across the membrane, the immobilized peptides
could destabilize the cell membrane. The high local concentration
of immobilized peptides was presumed to lead to the displacement
of positively charged counterions attached to the outer surface
layers. This could promote a dramatic change in bacterial surface
electrostatics, which could trigger the activation of autolytic
enzymes or the disruption of the ionic balance of more internal
layers. Hilpert et al. [71] also demonstrated that hydrophobic res-
idues at the exposed end of immobilized AMPs can have a major
inﬂuence on the antimicrobial activity. They suggested that theseresidues are responsible for the triggering connection between
AMPs and the bacteria cell wall.4. Covalent immobilization of an antimicrobial peptide
The toxicity sometimes associated with AMPs is usually related
to the high concentrations used to compensate for the relatively
short half-life of AMPs due to a rapid protease digestion [67], or
to peptide aggregation [11]. These characteristics have limited
the use of AMPs in applications that require systemic distribution
of the antimicrobial. However, AMPs are designed to work at local
surfaces in most of their natural applications. Thus, stable immobi-
lization of AMPs onto a biomaterial could be the pathway to over-
come these difﬁculties [72]. Covalent immobilization of AMP can
increase their long-term stability while decreasing their toxicity,
as compared to incorporation approaches on leach- or release-
based systems [11,35,36,69,72–75]. Furthermore, the proper orien-
tation of the peptide may result in enhanced activity [34]. Towards
this goal, the effect of AMP chemical immobilization on antimicro-
bial activity has been studied by several investigators [3,4,6,
25–27,29,48,49,71] (Table 1). In the current review, different
AMP surface covalent immobilization strategies are discussed,
focusing on the importance of solid supports and chemical cou-
pling strategies, spacer speciﬁcities (type, length and ﬂexibility),
surface density and exposure/orientation as determinants of
immobilized peptide biocidal and cytotoxic activity. As summa-
rized in Table 1, the various studies of immobilized AMPs differ
in important aspects, including the immobilization method
applied, the peptide sequence, mode of action of the AMPs used,
and the bacteria tested. These experimental variations make it
difﬁcult to achieve a straightforward comparison. Nevertheless,
important lessons can be derived from these diverse studies.
In 1995, Haynie et al. [67] demonstrated that some AMPs (nat-
ural occurring magainin 2 and several idealized synthetic amphi-
pathic peptides) immobilized onto a polyamide resin (pepsin K)
retained lethal activity against several Gram-positive and Gram-
negative bacteria. As already mentioned, these results demon-
strated that the interaction of magainin with the outer membrane
of the bacteria is sufﬁcient for their lethal activity, since the poten-
tial peptide penetration depth is very low due to the short spacer
(short 2 or 6 carbon chain linkers) used.
Willcox et al. [11] compared the antimicrobial activity of the
synthetic peptide melimine that was adsorbed or covalently immo-
bilized onto commercial contact lenses (Etaﬁlcon A). Covalent
Table 1
Overview of the reported AMP immobilization strategies.
AMP Substrate AMP immobilization strategy Microorganisms assessed
[67] Magainin 2 and
Related
synthetic
amphiphilic
peptides
Polyamide resin (pepsin K) Directly synthesized on polyamide resin, after
immobilization through their C-terminal amino acids
.  AMP orientation was controlled
 Short spacer, with 2- or 6-carbon chains, was used
 Stability to heat was studied
 no AMP release was observed
Escherichia coli ATCC 35695; and ATCC
25922, Staphylococcus aureus ATCC
25923 and ATCC 6538, Klebsiella
pneumoniae ATCC 4352, Bacillus subtilis
ATCC 6051, Candida albicans ATCC
10231, Aspergillus niger ATCC 6275, and
Pseudomonas aeruginosa ATCC 27853.
[1] Magainin I Non-fouling copolymer brushes based
on different percentages of:2-(2-
methoxyethoxy)ethyl methacrylate
(MEO2MA)/hydroxyl-terminated
oligo(ethylene glycol) methacrylate
(HOEGMA)
Peptide immobilized by its C-terminal amino acid
The process consisted of a previous incorporation of a
cysteine residue on the C-terminal of magainin, to be
reacted with the polymeric brushes via PMPI (N-(p-
maleimidophenyl)isocyanate)
 AMP orientation was controlled
 Brushes were used as spacers
 Different AMPs densities was tested
Listeria ivanovii, Bacillus cereus
[68] Magainin I Mixed OH/COOH-terminated self-
assembled monolayers (SAMs)
Immobilization by the free AMP amines after activation
of the COOH groups of the SAM with NHS/EDC
 AMP orientation was not controlled
 No spacers
 No AMP release was observed
L. ivanovii, Enterococcus faecalis and S.
aureus
[69] Magainin-
derived MK5E
and KLAL
PEGylated TentaGel S, HypoGel 400
and HypoGel 200 resin beads
C-terminally immobilized peptides were achieved by
standard solid-phase peptide synthesis and Fmoc (9-
ﬂuorenylmethoxycarbonyl)-chemistry
N-terminal and side-chain immobilization were
achieved by thioalkylation and oxime formation
 AMP orientation was controlled
 Different AMPs densities were tested
 Effect of PEGylated spacers was tested
 The haemolytic effect was assayed
E. coli strain DH5a, B. subtilis strain DSM
347
[11] Melimine Commercial contact lenses (etaﬁlcon
A)
Immobilization by the free AMP amines using 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide
 AMP orientation was not controlled
 No spacers
P. aeruginosa 6294, P. aeruginosa ATCC
15442, S. aureus Saur31, S. aureus CK5, S.
pneumoniae 010
[76] Melimine Glass coverslips Immobilization through the free AMP amines using two
different strategies:
 Using EDC after previous activation of the OH groups
of the glass surface with 4-azidobenzoic acid (ABA)
and irradiation with UV-light (320 nm)
 As above but using 4-ﬂuoro-3-nitrophenyl azide
(FNA) instead of ABA
 AMP orientation was not controlled
 No spacers
 Different AMP densities were tested
S. aureus strain 38, P. aeruginosa PA01
[70] Cathelin LL37 Silanized titanium surfaces:
Using glycidyloxypropyl
triethoxysilane (epoxy silane)
3-aminopropyl triethoxysilane(amino
silane)
 N-maleimidopropionic acid succinimide ester
 R-N-hydroxysuccinimidyl-ö-maleimidyl-PEG
 Effect of AMP orientation was tested
 Effect of PEGylated spacers was tested
 Different AMPs densities were tested
E. coli strain K12
[77] E14LKK Oxidized polyethylene ﬁlms (ox-PE) Immobilization by the terminal AMP amine (using
protected E14LKK side chains amines) with and without
PEGylated spacer onto ox-PE using 1-ethyl-3-(3-
aminopropyl)-carbodiimide
 AMP orientation was controlled
 Effect of PEGylated spacers was tested
E. coli ATCC 25922
[56] FKVKFKVKFK PEG-PS Resin beads Peptide–resin conjugates were synthesized by using
Fmoc (9-ﬂuorenylmethoxycarbonyl)-chemistry. To
investigate the effect of the resin on the activity, the b-
sheet peptide was conjugated with MBHA–resin
S. aureus ATCC 6538, Micrococcus luteus
ATCC 9341, P. aeruginosa ATCC9027,
E. coli ATCC 25922
[78] 6K8L PEG-PS resin beads The peptide was synthesized by solid-phase peptide
synthesis on a PEG-modiﬁed polystyrene resin (PEG-PS)
using Fmoc (9-ﬂuorenylmethoxycarbonyl)-chemistry.
The antimicrobial activity of the peptide–resin conjugate
was evaluated against different microorganisms.
B. subtilis (wild-type PB2, 168 Marburg
strain27), E. coli O157: H7 ATCC 33150,
Kluyveromyces marxianus, L.
monocytogenes ATCC 689426, P.
ﬂuorescence, Salmonella typhimurium H
3380 phage type DT 104, Serratia
liquefasciens and S. aureus ATCC 13566.
[71] 122 variant
peptides of 2
starting
sequences:
Bac2A and
Indolicidin
Cellulose
bifunctional resin TGS (1–6-dichloro-
1- Beta-dideoxy-Beta-fructofuranosM-
chloro-4-deoxy-galactopyranoside)
NH2/RAM (p-[(R,S)-a-[1-(9H-ﬂuren-9-
yl)-methoxyformamido]-2,4-
dimethoxybenzyl]-phen-oxyacetic
acid)
Microtiter plate
Peptides were:
 directly synthesized on a cellulose support using a
cellulose-amino-hydroxypropyl ether (CAPE) linker
chemistry or;
 directly synthesized onto a bifunctional resin or;
 directly bound to the microtiter plate via biotin–
streptavidin interaction.
 AMP orientation was controlled
 No spacers
Mini-Tn5-luxﬂiC::lux CDABE strain
H1001 of P. aeruginosa PAO1, S. aureus
ATCC 25923, C. albicans (lab isolate).
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amines (theN-terminal amino acid or the lysine side chain) without
a speciﬁc control on the orientation of the peptide onto the surface.
An apparent increase in efﬁcacy was observed when the peptide
was covalently attached to the surface, whichwas ascribed to a pos-
sibly higher relative surface availability of the peptide, in contrast
to the adsorption process where peptide aggregation could produce
uneven peptide distribution.
The effect of a-helix secondary structure of immobilized AMP
was also studied by Haynie et al. [67]. They demonstrated that only
those immobilized peptides still retaining their ability to form
amphipathic a-helices had antibacterial activity. Likewise, in the
work of Cho et al. [56], the secondary b-sheet structure was essen-
tial for antibacterial activity. Thus, these studies indicate that the
biocidal activity of immobilized AMPs is dependent on the pres-
ence of a well-established secondary structure.
Other important activity-modulating parameters include the
length, ﬂexibility and kind of spacer between the active sequences
and the solid matrices [67,69,70], the AMP surface density
[1,68,69], and orientation after immobilization [1,11,67–70,76–
78]. These parameters are discussed below.
4.1. Solid supports and chemical coupling strategies
A wide variety of solid supports has been assessed for produc-
tion of surfaces with immobilized AMPs, including polymeric
brushes and resins [1,56,67,69,71,77,78], metal (e.g. silanized
titanium) [70], glass coverslips [76], model surfaces (e.g.
self-assembled monolayers) [68], microtitre plates [71] and even
commercial contact lenses [11].
As shown in Table 1, the chemical strategies behind covalent
immobilization of peptides differ depending on the sequence, ori-
entation and position of the speciﬁc AMP, the presence/absence
of a spacer, or the spacer properties such as length and ﬂexibility.
Peptide immobilization may be carried out in a relatively ran-
dom manner, e.g. through formation of amide bonds between
amine groups from the pre-synthesized peptide and surface car-
boxyls (or the other way around, i.e. carboxyls from the peptide
reacting with surface amines), as in Refs. [10,43,44] (Table 1).
Alternatively, peptide immobilization can be controlled through
peptide construction (or immobilization) on the surface by chemo-
selective formation of a peptide–surface covalent bond, enabling
tethering in a predictable and deﬁned fashion.
Controlled immobilization is obviously preferred over random
tethering, as the former can be designed (i) to maintain peptide
structural motifs known to be relevant for activity, and (ii) to allow
exposure and ﬂexibility that more closely mimic the behaviour of
soluble AMPs. Uncontrolled immobilization can be especially det-
rimental when involving peptide amine groups, as these amine
groups are normally provided by lysines which are key amino acids
in the majority of cationic amphipathic AMPs [39–42].
The best way to control orientation of immobilized peptides is
to synthesize them directly onto the solid support (e.g. polyamide
resins, PEG-modiﬁed polystyrene resins, cellulose), as done in Refs.
[28,35,39] or [46] (Table 1). To this end, standard solid-phase pep-
tide synthesis (SPPS) methods may be used, such as the well-
established Fmoc/tBu strategy [79]. In this strategy selectively
protected amino acids are incorporated stepwise into the growing
peptide chain that is built from its C- to its N-terminal residue.
Once the peptide sequence is assembled, convenient treatment to
cleave off the amino acid side-chain-protecting groups is
performed.
An alternative to building the peptide directly onto the surface
is to pre-synthesize a peptide chain with a speciﬁc building block
incorporated in a selected position. This peptide chain can subse-
quently be chemoselectively attached to an adequately functional-ized surface. The most common approaches involve incorporation
of an additional cysteine into the peptide chain (e.g. [1]) or exploit-
ing a cysteine already available in the native sequence (if not cru-
cial for AMP activity), taking advantage of chemical reactions
speciﬁc to the thiol group. These reactions may include, as depicted
in Fig. 2, (i) disulﬁde bond formation between peptide and surface
thiols, as well as speciﬁc reactions of the peptide Cys thiol with (ii)
surface-bound maleimide groups [1,42], or (iii) surface-bound
epoxides (though these are generally reactive towards any nucleo-
philes, including lysine amines, and hence are not truly
chemoselective).
Other chemoselective approaches not involving Cys or other
thiol donors have been proposed more recently, namely those
involving Huisgen 1,3-dipolar cycloadditions, the so-called click-
reactions [80]. Here, the peptide can bear an additional azide
(e.g. from incorporation of 6-azidohexanoic acid) or an alkyne
donor (e.g. from incorporation of propynoic acid) to be ‘‘clicked
on’’ surface-bound alkyne or azide groups, respectively.
Both epoxide and click-based approaches have been used to
immobilize peptides and proteins onto surfaces (e.g. [81–83]),
but examples of their application to AMP tethering are still scarce.
Irrespective of alternatives available for peptide tethering onto
surfaces, careful comparative investigation of different strategies
must be carried out, in which the inﬂuence of peptide-surface
spacers, coupling chemistries and support materials on antimicro-
bial activity should be thoroughly analyzed. Only Hilpert et al. [71]
have assessed the effect of different support materials on the anti-
microbial activity, and found that, at least for their speciﬁc sys-
tems, the supports did not affect the activity of the tested peptides.
4.2. Inﬂuence of the spacer
Although some studies demonstrated that immobilized AMPs
have antimicrobial activity without incorporation of a spacer
[11,68,71,76], most protocols presented a spacer attachment step
[1,56,67,69,70,77,78], particularly with a PEG spacer with a MW
ranging from 3000 to 5400 [56,69,70,77,78]. The utilization of
PEG as a spacer presents several advantages. This polymer can
create non-adhesive surfaces due to its non-fouling characteristics,
thus preventing non-speciﬁc peptide binding to the surface and
shielding the peptides from the hydrophobic nature of a particular
biomaterial [56,77]. Studies comparing AMP immobilization with
and without PEGylated spacers demonstrated that some immobi-
lized AMPs are only bactericidal when a PEGylated spacer was used
[56,69,70,77]. For example, Gabriel et al. [70] demonstrated that
the LL37 peptide bound to titanium through a PEGylated spacer
was capable of killing Escherichia coli on contact. In marked con-
trast, LL37 peptide attached directly to the titanium surface dis-
played no antibacterial activity. The authors suggest that the use
of a long, ﬂexible PEG spacer provided a parallel peptide orienta-
tion and lateral mobility that were required for bactericidal activ-
ity. Bagheri et al. [69] also analyzed the inﬂuence of PEGylated
spacer length (3000, 400 and 200 Da) on bactericidal activity of
an amphipathic model KLAL peptide and magainin-derived
MK5E. They demonstrated that the antimicrobial activity of these
peptides distinctly decreased with reduction in the spacer length,
suggesting that the increased ﬂexibility associated with longer
spacers maximizes the antimicrobial activity of immobilized pep-
tides [69].
However, these results contradict those of Haynie et al. [67]
whose experiments indicated no difference in bactericidal activity
whether peptides were conjugated to the support with a two-car-
bon or a six-carbon chain linker [67]. In addition, Hilpert et al. [71]
reported that short 9-mers covalently linked without spacer have
bactericidal activity. They suggested an electrostatic interference
and destabilization rather than a penetrating mechanism.
Fig. 2. Examples of chemical strategies for controlled covalent attachment of AMPs on surfaces: (A) use of thiol-bearing peptides (Cys usually as thiol donor) for covalent
immobilization onto thiol-, maleimide- or epoxide-modiﬁed surfaces; (B) use of the Huisgen 1,3-dipolar cycloaddition for immobilization of either alkyne-bearing peptides
onto azide-modiﬁed surfaces or azide-bearing peptides onto alkyne-modiﬁed surfaces.
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materials, coupling chemistry and peptide orientations differ from
study to study. However, one can speculate that the requirement
for a spacer is directly associated with the mode of action of the
speciﬁc AMP.4.3. Peptide concentration
Peptide surface concentration depends on the immobilization
strategy used, as limited accessibility of the peptide reactive
groups and different coupling procedures can affect the efﬁciency
of peptide immobilization. Most studies indicate that peptide con-
centrations, albeit important, do not appear to be the most critical
parameter for antimicrobial activity [1,69,70,76]. Gabriel et al. [70]
observed that the bactericidal activity of LL37 immobilized onto
titanium surfaces was independent of the peptide concentration
[70]. Glinel et al. [1] demonstrated that the biocidal activity of
magainin I was not substantially reduced as the concentration of
immobilized peptide was reduced. Bagheri et al. [69] reported a
study aimed to determine the effect on bactericidal activity of dif-
ferent surface peptide densities and spacer lengths. These studies
demonstrated that an increase in the loading capacity of the resin
was not sufﬁcient to compensate for the decrease in activity due to
reduction of the spacer length. Based on these observations, they
concluded that spacer length has a more profound impact on activ-
ity than peptide concentration. Further, the maximum peptide
loading concentration was obtained with the C-terminal coupling
strategy, which correlated with higher Minimal Inhibitory Concen-
tration (MICs), suggesting that immobilization orientation can
compensate for low peptide loading [69].
Despite these reports, which strongly support the concept that
peptide surface loading levels are not a key factor in the antimicro-
bial activity of immobilized AMP, other studies have provided evi-
dence that the effects of peptide surface concentration cannot bedisregarded. For instance, Chen et al. [76] evaluated the effect of
melimine concentration after immobilization by two different
bifunctional azides (4-ﬂuoro-3-nitrophenyl azide (FNA) and 4-
azidobenzoic acid (ABA)) as crosslinking reagents. In this study,
the higher concentration of the peptide via ABA immobilization
correlated with a more profound antibacterial activity. Humblot
et al. [68] correlated low peptide concentrations with bacterio-
static rather than bacteriocidal effect of immobilized magainin I,
explaining that the low peptide concentration precludes the possi-
bility of multiple peptide entries into the cell membrane. In addi-
tion, Hilpert et al. [71] studied the effect of immobilized peptide
density on antimicrobial activity by utilizing different concentra-
tions of biotinylated peptide solutions with streptavidin-coated
plates. Antimicrobial activity was clearly concentration dependent,
decreasing sigmoidally as a function of decreasing peptide
concentration.4.4. Peptide orientation after immobilization
Different strategies for surface binding of peptides have been
conducted on different chain positions, such as C-terminal,
N-terminal and/or N-side-chain peptide attachment. As a result,
different peptide orientations and ﬂexibility were obtained, which
could be correlated with differential antimicrobial activities. The
chain position was determined based upon (i) previous knowledge
of peptide robustness to changes in given positions, i.e. on its
ability to retain or lose antimicrobial activity upon deletion of
N-terminal or C-terminal amino acids or amino acid segments;
(ii) the availability of functional groups suitable for a particular
coupling chemistry; or (iii) the promotion of parallel alignment
of peptide chains [56,67,68,70]. The studies of Gabriel et al. [70]
and Steven et al. [77] compared the antimicrobial efﬁciency of
N-terminally and N-side-chain immobilized peptides. They
performed site-speciﬁc activation and coupling by blocking the
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were different in the respective studies, only N-terminally attached
peptides displayed antimicrobial activity. Gabriel et al. [70] con-
cluded that only N-terminal conjugation permitted the appropriate
parallel orientation of the peptide helices, which is required for
interaction among the peptide molecules and between the pep-
tides and the lipid double layer during membrane pore formation.
These results are supported by the reported key role of basic lysine
side-chains (and of those from other basic amino acids, as arginine
or histidine) in the bioactivity of cationic AMP [39–42], which
could explain the deleterious effect of AMP immobilization
through Lys e-amino groups towards antimicrobial activity. The
possibility of C-terminal peptide immobilization should be
considered as this orientation may achieve similar speciﬁc activity
as N-terminal conjugation. Bagheri et al. [69] compared the activity
proﬁle of C-terminal, N-terminal and N-side-chain immobilized
AMP sequences. Slightly different results were obtained depending
on the speciﬁc peptide sequence and bacteria tested. C-terminally
attached AMPs displayed higher MICs, compared to N-terminal and
N-side-chain immobilization. The N-immobilization orientations
presented similar results, suggesting that the blockage of the cat-
ionic Lys side chains was of minor importance to the overall anti-
microbial activity. However, it is possible that the observed
reactivity pattern may be speciﬁc to the systems used by these
authors, where the AMP orientation appeared to be less relevant
when peptides were immobilized using long and ﬂexible spacers
[69]. Hilpert et al. [71] used a different strategy to screen the efﬁ-
ciency of immobilized AMPs. They rearranged the sequence of a
known active peptide and C-terminally immobilized the different
variants. They concluded that the placement of cationic residues
close to the linker site correlated with increased antimicrobial
activity as compared with peptides with cationic residues localized
to the N-terminus or within the middle portion of the peptide. The
positioning of hydrophobic residues proximal to the N-terminus
was critical to the activity of their immobilized AMPs.4.5. Activity efﬁciency of immobilized AMPs
Only a few studies have described an experimental comparison
of soluble and immobilized AMPs [56,67,69,71]. However, a straight-
forward comparison between MICs of soluble and immobilized
AMPs is very difﬁcult because precise quantiﬁcation of immobi-
lized AMP can be problematic. In most cases the immobilized
AMPs displayed an increase in their MIC value compared to the sol-
uble peptide. In studies by Haynie et al. [67] the immobilized AMPs
presented a 50-fold higher MIC compared to soluble peptides.
These investigators suggested that the coupling chemistry may
have resulted in more covalently bound peptide in the resin inte-
rior than on the surface, which could explain the higher concentra-
tion needed for activity. Cho et al. [56] found an extensive variation
range in the observed MIC values which were augmented 8- or
64-fold depending on the bacteria evaluated (E. coli,Micrococcus lu-
teus and S. aureus more sensitive; P. aeruginosa less susceptible). In
the Bagheri et al. [69] studies, the active concentrations increased
about 100-fold from the micromolar MICs of the soluble peptides
to the milimolar range of the immobilized-AMPs. All these studies
reported MIC increases that varied with peptide and bacteria
speciﬁcity.
However, Hilpert et al. [71] compared soluble MICs and inhibi-
tion of luminescence by immobilized AMPs. No correlation of
antimicrobial activity was observed between soluble and immobi-
lized AMPs, as inactive soluble AMPs presented activity when
immobilized, and some active soluble AMPs lost activity when
immobilized.4.6. Cytotoxicity
KLAL and MK5E are examples of immobilized AMPs for which
haemolytic activity has been assessed. The KLAL- and MK5E-
soluble haemolytic concentrations (EC25) were at least 16-fold
higher than the respective MIC. Moreover, the haemolytic activity
levels of the immobilized-peptide beads and the bare beads were
indistinguishable from each other. This observation leads to the
conclusion that both immobilized peptides at their MICs are inac-
tive toward red blood cells [69]. Hilpert et al. [71] assessed cyto-
toxicity of a battery of immobilized peptides through human red
blood cell haemolysis. They reported that the immobilization of
AMPs had a reduced haemolytic activity when compared with
the soluble counterpart. Thus, these initial studies indicate that
peptide immobilization does not enhance the haemolytic proper-
ties of the peptides, and may actually reduce potential haemolysis
when compared to soluble peptides.4.7. Long-term stability
In order to check the activity persistence of immobilized pep-
tides, investigators have subjected the modiﬁed surfaces to various
harsh procedures, such as washing operations, heat treatments, pH
variations and long-term activity assessment [11,67,68,78]. In the
washing inﬂuence study, two different AMP-modiﬁed resin beads
were extensively washed without loss of antimicrobial activity
[67,78]. The heat stability experiment was conducted to evaluate
whether exposure of AMP to autoclaving (121 C for 20 min) or
to a dry oven (200 C for 30 min) would alter the ability of the pep-
tide to inhibit bacterial growth. The bactericidal efﬁcacy of the
heat-treated 6K8L was maintained under both heating conditions
[78]. In addition, the antimicrobial efﬁcacy of melimine was main-
tained during autoclaving [11]. Cole et al. [84] veriﬁed that the lev-
els of melimine in lenses after removal, cleaning and sterilization
did not differ from those determined before 24 h of use. The effect
of pH on the modiﬁed surface was assessed. The peptide 6K8L
immobilized on PEG-poly(styrene) resin beads retained its antimi-
crobial activity over a pH range of 3.5–7 in citrate buffer, although
bacterial killing was signiﬁcantly greater at pH 3.5 than at pH 7
[78], possibly due to the higher positive charge at the lower pH.
Humblot et al. [68] assayed the stability of antimicrobial activity
of immobilized peptide at various times over a 6 month period.
Samples were cleaned, dried and stored at 4 C, between each anti-
bacterial activity assay. The results showed that the peptide re-
mained active over the 6 month period, even though the activity
of the immobilized peptide was reduced at the 6 month time point.
All these studies, although limited, point to remarkably high
long-term stability and resistance of immobilized AMP to environ-
mental conditions.5. Conclusions
Infections associated with the use of biomaterials remain one of
the major barriers to the long-term use of medical devices in pa-
tients. Colonization of biomedical surfaces is considered the basis
for bioﬁlm formation and infection. The establishment of a bioﬁlm
results in lower antibiotic activity, and higher antibiotic resistance,
which in turn can demand implant removal. There is a clear need
for a broad-spectrum antimicrobial that prevents colonization of
biomaterials, without damaging mammalian cells, that minimizes
the potential for bacterial resistance, and that is stable throughout
the sterilization process. AMPs have enormous potential to fulﬁl all
these requirements and are therefore suitable for the generation of
antimicrobial surfaces. Different approaches may be applied to
improve surfaces with such antimicrobial agents. Covalent
F. Costa et al. / Acta Biomaterialia 7 (2011) 1431–1440 1439immobilization of AMPs to surfaces can offer important advanta-
ges, including long-term stability and lower toxicity when com-
pared to leach- or release-methodologies. The implications of the
studies reviewed herein suggest that immobilized AMPs may be
effective in the prevention of bioﬁlm formation by reduction of
microorganism survival post-contact with the coated material.
The mechanisms of action behind each antimicrobial coating vary
according to the speciﬁc AMP, chemistry and support used. More-
over, the overall comparison of results suggests that free and
immobilized AMPs may act through different mechanisms. Further
studies may clarify the mechanisms of action underlying immobi-
lized AMPs and their potential use in health applications as
antimicrobial coatings of medical devices.
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